Bio-Techne Corp. is acquiring Exosome Diagnostics Inc. to complement its existing Advanced Cellular Diagnostics (ACD) business with Exosome's biofluid-based diagnostics, and to take advantage of the emerging precision-medicine trend.
"Exosome Diagnostic's technology is a game-changer, and positions Bio-Techne to be a leader in the rapidly-growing noninvasive liquid biopsy market," Bio-Techne CEO Charles Kummeth said June 25th
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?